On August 30, 2022 I-Mab reported that it would concentrate its drug development efforts on five key candidates, for which it will seek international partners once the candidates show Phase I or II proof of concept (Press release, I-Mab Biopharma, AUG 30, 2022, View Source [SID1234618928]). It plans to out-license ex-China rights, while retaining China rights, though it will also partner commercialization in China to avoid the cost of building a sales force. The detailed presentation of the company’s assets seems an oblique denial that I-Mab is seeking to sell the entire company, a possibility raised in recent press reports. I-Mab pointed out that it has almost $600 million in cash, enough to support three years of operations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!